Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience (TWST) insider Paula Green, SVP of Human Resources, reported a transaction on 11/03/2025. She sold 1,084 shares of common stock at $32.0794 per share. According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon the vesting of Restricted Stock Units and did not represent a discretionary trade. Following the transaction, she beneficially owns 142,187 shares directly.
Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a Form 4 transaction: she sold 4,887 shares of common stock on 11/03/2025 at $32.0794 per share.
According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon RSU vesting, and not a discretionary trade. Following the transaction, she beneficially owns 733,922 shares directly.
She also holds employee stock options, including 266,539 at $26.66 expiring 11/18/2028 and 150,879 at $8.82 expiring 09/28/2027.
Twist Bioscience (TWST) disclosed an insider transaction by its Chief Accounting Officer, Robert F. Werner. On 11/03/2025, he sold 160 shares of common stock at $32.0794 in a mandated sell-to-cover to satisfy tax withholding arising from the vesting of restricted stock units under the company’s equity plan. Following the transaction, his beneficial ownership stood at 50,870 shares.
Twist Bioscience (TWST) filed a Form 4 reporting an insider tax-related sale. On 10/30/2025, a company officer executed a mandated "sell-to-cover" of 6,515 shares of common stock at $31.4443 per share to satisfy tax withholding tied to the vesting of Performance Stock Units. The filing notes these were not discretionary trades.
Following the transaction, the reporting person directly owned 121,713 shares. The insider is identified as Senior Vice President, Chief Legal Officer & Corporate Secretary.
Twist Bioscience (TWST) reported an insider transaction by President and COO Patrick John Finn. On 10/30/2025, he sold 17,606 shares of common stock at $31.4443 per share, coded “S.” The filing states these shares were sold solely to cover tax withholding triggered by the vesting of Performance Stock Units under a mandated “sell to cover” election in the company’s equity plans, indicating they were not discretionary trades.
Following the transaction, Finn beneficially owns 268,674 shares, held directly.
Twist Bioscience (TWST) reported an insider transaction by its SVP of Human Resources, Paula Green. On 10/30/2025, she sold 6,920 shares of common stock (transaction code S) at $31.4443 per share. The filing states these shares were sold to satisfy tax withholding obligations from vesting Performance Stock Units via a mandated “sell to cover,” indicating they were not discretionary trades. Following the transaction, she beneficially owned 143,271 shares, held directly.
Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a transaction on 10/30/2025: the disposition of 31,379 shares of common stock at $31.4443 per share. The filing states these shares were sold to cover tax withholding tied to the vesting of performance stock units, pursuant to the company’s equity plan “sell to cover” election, and were not discretionary trades.
Following the transaction, Leproust beneficially owns 738,809 common shares directly. Derivative holdings listed include employee stock options, such as 150,879 options at an exercise price of $8.82 and 266,539 options at $26.66, among others with varying vesting and expiration terms.
Twist Bioscience (TWST) reported an insider transaction by its Chief Financial Officer, Adam Laponis. On 10/30/2025, the CFO sold 5,517 shares of common stock at $31.4443 per share. According to the filing, these shares were sold to satisfy tax withholding obligations tied to the vesting of Performance Stock Units and were executed as a mandated “sell to cover,” not a discretionary trade.
Following the transaction, the reporting person beneficially owns 111,008 shares directly.
Twist Bioscience (TWST) insider transaction: the Chief Accounting Officer reported a sale of 1,016 shares of common stock on 10/30/2025 at a price of $31.4443 per share. The filing states the sale was a mandated “sell to cover” to satisfy tax withholding obligations tied to the vesting of Performance Stock Units, and not a discretionary trade. Following the transaction, the reporting person beneficially owned 51,030 shares, held directly.
Twist Bioscience (TWST): insider equity award update. President and COO Patrick John Finn acquired 79,785 shares of common stock at $0 on October 28, 2025, recorded as an “A” (acquisition). Following this transaction, he beneficially owns 286,280 shares directly. The shares reflect Performance Stock Units for which target criteria were determined to have been met on October 28, 2025. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration as provided in the award agreement.